Focus 1: Rongchang Biologics - Rongchang Biologics signed an exclusive licensing agreement with AbbVie for RC148, potentially receiving up to $4.95 billion in milestone payments [2] - The agreement includes an initial payment of $650 million and tiered royalties based on net sales outside Greater China [2] - This licensing deal is expected to accelerate the global development and commercialization of RC148, enhancing the company's brand value and international influence [2] Focus 2: Jianghuai Microelectronics and Huashi Technology - Jianghuai Microelectronics announced a major matter that may lead to a change in control, resulting in a stock suspension starting January 13, 2026, for up to two trading days [3] - Huashi Technology's major matter also involves potential control changes, with stock suspension effective January 13, 2026, for a similar duration [3] Focus 3: Zhi Te New Materials and *ST Chengchang - Zhi Te New Materials' stock was suspended for review after a 198.57% increase over six consecutive trading days [4] - *ST Chengchang's stock was also suspended due to significant trading anomalies, with four instances of abnormal trading within ten days [4] Earnings Highlights - WuXi AppTec expects a revenue of approximately ¥45.46 billion for 2025, a year-on-year increase of about 15.84%, with a projected net profit of approximately ¥19.15 billion, up 102.65% [6] - Chao Hong Ji anticipates a net profit of ¥436 million to ¥533 million for 2025, representing a growth of 125% to 175% [7] - Asia-Pacific Co. forecasts a net profit of ¥468 million to ¥575 million for 2025, reflecting a growth of 120% to 170% [7] - New Farm Co. expects a net profit of ¥87 million to ¥105 million for 2025, a growth of 50.71% to 81.89% [7] - Cangge Mining anticipates a net profit of ¥3.7 billion to ¥3.95 billion for 2025, a growth of 43.41% to 53.1% [7] - Lianhua Holdings expects a net profit of ¥290 million to ¥330 million for 2025, a growth of 43.15% to 62.90% [8] - Bojun Technology forecasts a net profit of ¥828 million to ¥1.012 billion for 2025, a growth of 35% to 65% [8] - Sanxiang New Materials expects a net profit of approximately ¥100 million to ¥130 million for 2025, a growth of 31.99% to 71.58% [8] Important Matters - Blue Arrow Electronics signed a share acquisition intention agreement to acquire at least 51% of Chengdu Xinyi Technology, with a valuation of up to ¥675 million [12] - The acquisition aims to integrate semiconductor packaging and testing with chip design, enhancing industry synergy [12] - Shanghai Airport received notification of a significant share increase by Taibao Asset, raising its stake to 5% [24] - Kaipu Biotech's actual controller increased shareholding through a block trade, with plans for further purchases [24]
筹划重大事项！603078、301218，周二起停牌